Condition
Corneal Graft Rejection
Total Trials
3
Recruiting
0
Active
0
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 80/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 3 (1)
Trial Status
Terminated1
Unknown1
Completed1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT05009407CompletedPrimary
CD160 Expression in Corneal Vessels
NCT02206789Not ApplicableUnknownPrimary
Evaluation of the Efficacy of 2% Cyclosporine in Preventing Graft Rejection
NCT00447642Phase 3Terminated
Study to Assess LX201 for Prevention of Corneal Allograft Rejection or Graft Failure in Subjects Who Have Experienced One or More Rejection Episodes Following Penetrating Keratoplasty
Showing all 3 trials